Linezolid-Associated Neurologic Adverse Events in Patients with Multidrug-Resistant Tuberculosis, France

Details

• Alternative Title:
  Emerg Infect Dis
• Personal Author:
  Jaspard, Marie ; Butel, Nathalie ; El Helali, Najoua ; Marigot-Outtandy, Dhiba ; Guillot, Helene ; Peytavin, Gilles ; Veziris, Nicolas ; Bodaghi, Bahram ; Flandre, Philippe ; Petitjean, Gregoire ; Caumes, Eric ; Pourcher, Valerie
• Description:
  Linezolid is one of the most effective drugs for treating multidrug-resistant tuberculosis (MDR TB), but adverse effects remain problematic. We evaluated 57 MDR TB patients who had received >1 dose of linezolid during 2011-2016. Overall, patients received 600 mg/day of linezolid for a median of 13 months. In 33 (58%) patients, neurologic or ophthalmologic signs developed, and 18 (32%) had confirmed peripheral neuropathy, which for 78% was irreversible at 12 months after the end of TB treatment despite linezolid withdrawal. Among the 19 patients who underwent ophthalmologic evaluation, 14 patients had optic neuropathy that fully reversed for 2. A total of 16 (33%) of 49 patients had a linezolid trough concentration >2 mg/L, and among these, 14 (88%) experienced adverse effects. No significant association was found between trough concentration and neurologic toxicity. These findings suggest the need to closely monitor patients for neurologic signs and discuss optimal duration of linezolid treatment.
• Subjects:
  France Linezolid Linezolid-Associated Neurologic Adverse Events In Patients With Multidrug-Resistant Tuberculosis, France MDR TB Neurologic Events Neuropathy Pharmacokinetics Research TB Tuberculosis Tuberculosis And Other Mycobacteria XDR TB

  More +
• Source:
  Emerg Infect Dis. 26(8):1792-1800
• Pubmed ID:
  32687026
• Pubmed Central ID:
  PMC7392460
• Document Type:
  Journal Article
• Volume:
  26
• Issue:
  8
• Collection(s):
  Emerging Infectious Diseases
• Main Document Checksum:
  urn:sha256:293f986a290c5470442f9b36cc714117140aa409fec07771aecc13967205e1d2
• Download URL:
  https://stacks.cdc.gov/view/cdc/91534/cdc_91534_DS1.pdf
• File Type:
  [PDF - 589.87 KB ]